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Abstract It has been suggested that cyclooxygenase-2
(COX-2)-mediated prostaglandin synthesis is associated
with liver inXammation and carcinogenesis. The aim of this
study is to identify the cellular source of COX-2 expression
in diVerent stages, from acute liver injury through liver
Wbrosis to cholangiocarcinoma (CC). We induced in rats
acute and “chronic” liver injury (thioacetamide (TAA) or
carbon tetrachloride (CCl4)) and CC development (TAA)
and assessed COX-2 gene expression in normal and dam-
aged liver tissue by RT-PCR of total RNA. The cellular
localization of COX-2 protein in liver tissue was analyzed
by immunohistochemistry as well as in isolated rat liver
cells by Western blotting. The Wndings were compared with
those obtained in human cirrhotic liver tissue. The speciWc-
ity of the antibodies was tested by 2-DE Western blot and
mass spectrometric identiWcation of the positive protein
spots. RT-PCR analysis of total RNA revealed an increase
of hepatic COX-2 gene expression in acutely as well as
“chronically” damaged liver. COX-2-protein was detected
in those ED1+/ED2+ cells located in the non-damaged tis-
sue (resident tissue macrophages). In addition COX-2 posi-
tivity in inXammatory mononuclear phagocytes (ED1+/
ED2¡), which were also present within the tumoral tissue
was detected. COX-2 protein was clearly detectable in
isolated KupVer cells as well as (at lower level) in iso-
lated “inXammatory” macrophages. Similar results were
obtained in human cirrhotic liver. COX-2 protein is consti-
tutively detectable in liver tissue macrophages. InXamma-
tory mononuclear phagocytes contribute to the increase of
COX-2 gene expression in acute and chronic liver damage
induced by diVerent toxins and in the CC microenviron-
ment.
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COX-1 and COX-2 are two isoforms of the enzyme
cyclooxygenase (COX), also known as prostaglandin H
synthase (PGHS) or prostaglandin endoperoxide synthase
(PTGS). Both COX isoforms are associated with inner
membranous compartments (Bayly et al. 1999; Picot et al.
Two brief statements Expression of cyclooxygenase-2 (COX-2) is 
restricted to tissue macrophages and to recruited mononuclear 
phagocytes in rat liver injury and cholangiocarcinoma. Our results 
indicate that the targets of COX-2 inhibitors are not the tumor cells 
themselves, but the tissue macrophages of the tumor 
microenvironment.
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1994) and represent key enzymes in the conversion of ara-
chidonic acid to prostaglandin (PG). COX-1 is constitu-
tively expressed in most cell types and is involved in the
homeostasis of various physiological functions, while
COX-2 is considered to be a mitogen-inducible form,
associated with biologic events such as injury, inXamma-
tion, and proliferation (O’Banion et al. 1991,  1992;
Kirschenbaum et al. 2000). COX-2 gene expression was
demonstrated in vitro in diVerent cell types, e.g. in mono-
cytes, human umbilical vein endothelial cells, vascular
smooth muscle cells, and Wbroblasts (Hla and Neilson
1992), but only a few data are available for tissue macro-
phages (Ahmad et al. 2002).
COX-2-derived PGE2 can stimulate angiogenesis by
induction of the vascular endothelial growth factor (Sim-
mons et al. 2004; Tsujii et al. 1998). Furthermore, it has
been shown that tumor angiogenesis and growth of
explanted tumors are reduced in COX-2 null mice (Wil-
liams et al. 2000). PGE2 also has an eVect on the immune
system by regulating cytokine production in leukocytes
(Betz and Fox 1991; Kunkel et al. 1986a; Kunkel et al.
1988; Kunkel et al. 1986b). Bennett et al. (1977) showed
that large amounts of PGs are produced by certain tumor
cells and it has been suggested that PGE2 is associated with
cancer through depression of the immune system (Simmons
et al. 2004). It is therefore believed that COX-2 plays an
important role in carcinogenesis and COX-2 has been stud-
ied extensively as a key rate-limiting enzyme for prostanoid
biosynthesis.
COX-2 has been implicated in the carcinogenesis of var-
ious human cancers, including colorectal cancer and also
CC (Endo et al. 2002; Gasparini et al. 2003; Hu 2003; Han
et al. 2004; Han and Wu 2005; Wu 2005; Eisinger et al.
2007; Zhang et al. 2005). In many cases, however, the pres-
ence of mononuclear phagocytes in the tumor samples has
not been considered.
Several conXicting reports exist in the literature about
COX-2 expression in liver. For example, some publications
described COX-2 immunodetection in normal or damaged
hepatocytes, and it has been suggested that COX-2 expres-
sion could be related to the inXammatory phenomena pres-
ent in the early phases of diVerent chronic liver diseases
and is probably also related to the induction of hepatocarci-
nogenesis (Chariyalertsak et al. 2001; Giannitrapani et al.
2009) while others have established that adult hepatocytes
fail to express the COX-2 gene (Casado et al. 2007;
Mohammed et al. 2004). Furthermore, COX-2 positivity
has been described in CC cells by immunohistology using
immunoperoxidase staining (Endo et al. 2002).
COX-2 has attracted particular interest because of the
cancer preventive and therapeutic potential of its inhibition
and because of its possible role in the early phases of CC
development. Furthermore, in several reports it has been
assumed that malignant cells became able to express the
COX-2 gene and that these cells may be the target of COX-
2 inhibitors (Zhang et al. 2004; Thakur and Sanyal 2010).
In fact, it has been shown that COX-2 inhibitors reduced
the in vitro growth of 5 human COX-2-expressing CC cell
lines (Zhang et al. 2004).
We recently established an animal model of CC in the
rat by administering TAA in drinking water which have
morphological similarities with CC observed in human
pathology (Mansuroglu et al. 2009a,b). We investigated the
expression of COX-2 at various stages of acute and chronic
liver injury up to CC development using this model. More-
over, we worked at identifying the cell type(s) expressing
COX-2 in the same rat liver. For comparison one other rat
model of hepatocellular damage and inXammation was
used. In addition, human liver tissue samples were also
studied. We found that COX-2 protein is constitutively
expressed in liver tissue macrophages and that the
increased expression during inXammation is however not
only due to an upregulation of the gene in those cells but
newly recruited inXammatory mononuclear phagocytes
also contribute to increased COX-2 gene expression. Nei-
ther hepatocytes nor CC cells seem to be able to express
COX-2 in this experimental setting.
Materials and methods
Chemicals and antibodies
The majority of the chemicals and solutions used were pur-
chased from Sigma (Steinheim, Germany): DL-dithiothreitol
(DTT), lipopolysaccharide (LPS), phenylmethylsulfonyl Xuo-
ride (PMSF), phorbol 12-myristate 13-acetate (PMA), phos-
phatase inhibitor cocktail 1 and 2, TAA, thiourea, urea; from
Merck KGaA (Darmstadt, Germany): glycerine, HCl; from
PAA Laboratories GmbH (Cölbe, Germany) we purchased:
RPMI 1640 medium, fetal calf serum (FCS), penicillin/
streptomycin, and phosphate-buVered saline (Dulbecco’s
PBS); were obtained from Biochrom AG (Berlin, Germany):
medium M199, L-glutamine and from Bio-Rad (Munich,
Germany): a Bio-Rad protein assay kit and ampholytes (Bio-
Lyte® 3/10). Bromphenol blue and Tris came from Carl Roth
GmbH (Karlsruhe, Germany) and 3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate (CHAPS) from
AppliChem GmbH (Darmstadt, Germany). Bovine serum
albumin (BSA) and sodium dodecyl sulfate were purchased
from Serva (Heidelberg, Germany). Primer pairs of COX-2,
ED1, ubiquitin C (UBC), protector RNAse inhibitor, and
1x RT buVer were supplied by Invitrogen (Darmstadt,
Germany). Fast Sybr Green master mix was supplied by AB
(Applied Biosystem, USA). 4’,6-diamidino-2-phenylindole
(DAPI) was delivered by Molecular Probes (Leiden, TheHistochem Cell Biol (2012) 137:217–233 219
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Netherland) and moloney murine leukaemia virus reverse
transcriptase (M-MLV RT) by Promega (Mannheim, Ger-
many). The antibodies used in this study are shown in
Table 1.
Animals
Male Sprague–Dawley rats weighing 330–370 g were
used for TAA and CCl4 experiments; they were provided
by Charles River (Sulzfeld, Germany) and Harlan Win-
kelmann (Borchen, Germany). The animals were kept
under standard conditions with 12-h light/dark cycles;
food and water were available ad libitum and they
received care according university policies and the rele-
vant guidelines for care and use of laboratory animals of
the German National Institute of Health. All animal
experiments performed were approved by the ethics
review board and were constantly supervised by the local
ethics commission. Animals of all experimental groups
were killed under pentobarbital anesthesia. Livers were
rinsed and snap-frozen in liquid nitrogen. Samples were
stored at ¡80°C until further use. All experiments were
repeated in three series. Four animals were killed at each
time point.
Induction of acute liver injury, liver Wbrosis, and CC 
development by TAA
Acute liver damage was induced by a single intraperitoneal
(i.p.) injection of TAA dissolved in sterile sodium saline.
Control rats received only a single i.p. injection of sterile
sodium saline. Four animals in each group were killed 1, 3,
6, 12, 24, 48, 72 and 96 h after a single-dose TAA adminis-
tration.
Induction of liver Wbrosis and CC by TAA administra-
tion was conducted according to Yeh et al. (2008) as
described elsewhere (Mansuroglu et al. 2009a, b). Animals
were divided into two groups, i.e. a control group and an
experimental group. The experimental group received TAA
in their drinking water every day up to the time they were
euthanized. Four animals in each group were killed at vari-
ous time points. By week 16, 80% of the TAA-treated rats
had developed CC and the experiment was stopped at week
18, when 100% of the TAA-treated rats had developed CC.
Induction of acute and chronic liver injury by CCl4
Acute liver damage was induced by orally administered
CCl4 as described previously (Knittel et al. 1999; Neubauer
Table 1 The antibodies used in this study
Clone SpeciWcity Applications Dilution Source
33/Cox-2 Anti-COX-2 mouse monoclonal WB: 1D, 2D 1:100, 1:100 BD Transduction Laboratories (Heidelberg, Germany)
IHC 1:50
– Anti-COX-2 (H-62; sc-7951) rabbit polyclonal WB: 2D 1:100 Santa Cruz Biotechnology (Heidelberg, Germany)
– Anti-COX-2 (N-20; sc-1746) goat polyclonal WB: 2D 1:100
– Anti-COX-2 (ab15191) rabbit polyclonal WB: 1D, 2D 1:100, 1:100 Abcam plc (Cambridge, UK)
IHC 1:100
b170 Anti-CK-19 mouse monoclonal IHC 1:50 Leica Biosys. Newcastle Ltd. (Newcastle, UK)
OCH1E5 Anti-Hep Par-1 mouse monoclonal IHC 1:50 DAKO (Hamburg, Germany)
PG-M1 Anti-human CD68 mouse monoclonal IHC 1:100
ED1 Anti-ED1 mouse monoclonal WB: 1D 1:200 AbD Serotec (Oxford, UK)
IHC 1:50
ED2 Anti-ED2 mouse monoclonal IHC 1:50
Secondary antibodies
Polyclonal rabbit anti-mouse immunglobulins/HRP WB: 1D, 2D 1:1,000 DAKO (Hamburg, Germany)
Polyclonal rabbit anti-goat immunglobulins/HRP WB: 1D, 2D 1:1,000
Polyclonal swine anti-rabbit immunglobulins/HRP WB: 1D, 2D 1:1,000
AlexaFluor-555-conjugated
goat anti-rabbit IgG




APAAP consists of soluble complexes of calf intestinal alkaline phosphatase and mouse monoclonal anti-alkaline phosphatase
AP7/6/7 Anti-alkaline phosphatase
mouse monoclonal
IHC 1:20 DAKO (Hamburg, Germany)
– Rabbit anti-mouse immunglobulins (Z 0259) IHC 1:20220 Histochem Cell Biol (2012) 137:217–233
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et al. 1995). A single dose of 150 l CCl4/corn oil solution
(50%, v/v) per 100 g body weight was given to each rat.
Control rats received only corn oil. Rats were killed 3, 6, 9,
12, 24, 48, 72, and 96 h after the CCl4 administration.
Chronic liver injury was induced according to the proto-
col by Proctor and Chatamra (1982). The experimental
group received CCl4 orally once a week. After a period of 8
and 13 weeks, the animals were killed and livers were
obtained.
Isolation of hepatocytes, tissue macrophages 
(KupVer cells), and myoWbroblasts from rat livers
Hepatocytes from male Sprague–Dawley rats were isolated
by in situ perfusion and cultured as reported previously
(Neubauer et al. 1995; Knittel et al. 1992). KupVer cells
and myoWbroblasts of normal liver were isolated as
described by Knook and Sleyster (1976) with some modiW-
cations (Armbrust et al. 1993; Neubauer et al. 2008).
Isolated cells were cultured for 24 h and protein extracts
were prepared from KupVer cells, hepatocytes, and myoW-
broblasts. For mRNA isolation, KupVer cells (in duplicate)
were stimulated with 10 g/ml LPS, and mRNA was
obtained 2, 4, and 6 h from LPS-treated as well as from
control cultures.
Isolation of mononuclear phagocytes from damaged 
rat livers
Mononuclear phagocytes from TAA- and CCl4-damaged
rat livers were isolated by in situ perfusion. Centrifugal elu-
triation was performed to separate small KC from large
KC. The Wrst fraction was collected at Xow rates ranging
from 19 up to 28 ml/min (Beckmann centrifuge J2-21, J-6B
rotor, 2,500 rpm) and the second fraction at Xow rates rang-
ing from 28 up to 55 ml/min. Each fraction was sedi-
mented, resuspended in culture medium (M199, 15% FCS,
100 U penicillin/ml, 100 g streptomycin/ml), and counted
in a Neubauer chamber after Trypan Blue-staining. Cells
were then plated onto 24-well plates (5 £ 105 cells/well).
Two hours after plating, the cultures were washed inten-
sively to eliminate non-adherent cells. Cultures were kept
in a 5% CO2 atmosphere and saturated humidity at 37°C.
Total protein extracts and mRNA were obtained.
Human liver tissue
Four specimens of cirrhotic human livers were obtained
from patients undergoing transplantation after developing
HCC or CC and four specimens of cirrhotic liver without
tumor. Specimens were frozen in liquid nitrogen immedi-
ately after surgical removal. Human liver samples were
used for immunohistochemical analysis.
Culture and activation of macrophage cell line
The monocytic/macrophage cell line RAW 264.7 (Lüder
et al. 2003; Raschke et al. 1978) was a gift from the Depart-
ment of Bacteriology, Georg-August University Goettingen
(UMG, Goettingen, Germany). RAW 264.7 cells were
incubated with RPMI 1640 medium containing 10% FCS,
100 U/ml penicillin, 100 mg/ml streptomycin, 2 mmol/l
L-glutamine, and 2.5 g/l D-glucose at 37°C, 20% O2, and 5%
CO2. Cells were used to determine the speciWty of COX-2
antibody binding and the eVect of stimulation on COX-2
expression. Cells were activated with 10 g/ml LPS and
10 ng/ml PMA. PMA was dissolved in DMSO (0.5 mg/ml)
and aliquots were stored at ¡20°C; LPS was dissolved in
PBS. Control cells were incubated with the DMSO vehicle
only. For protein or mRNA isolation, cells were seeded at
0.2 £ 107 cells in 75 cm2 tissue culture Xasks (Sarstedt AG
& Co., Nümbrecht, Germany).
RNA isolation and real-time PCR
RNA was isolated from all control and TAA-treated rat liv-
ers. RNA quality was tested by agarose gel electrophoresis
and visualized with UV light. RNA concentration was
quantiWed by measuring the absorbance at 260/280 nm. The
cDNA was generated by reverse transcription of 3.0 g of
total RNA with 100 nmol/l of dNTPs, 50 pmol/l of primer
oligo(dT)15, 200 units of M-MLV RT, 16 units of protector
RNAse inhibitor, 1£ RT buVer, and 2.5 ml of 0.1 mol/l
DTT for 1 h at 40°C as described previously (Kondo et al.
1999). Gene expression of COX-2 (forward primer 5-TAC
CGGACTGGATTCTAG-3, reverse primer 5-AAGTTG
GTGGGCTGTCAATC-3), and ED1 (forward primer 5-A
TTGAACCCGAACAAAACCA-3, reverse primer 5-GC
TTGTGGGAAGGACACATT-3) were analyzed using a
Fast Sybr Green master mix. UBC (forward primer 5-CAC
CAAGAAGGTCAAACAGGAA-3, reverse primer 5-AA
GACACCTCCCCATCAAACC-3) was used as house-
keeping gene in the TAA model. The ampliWcation was
performed through two-step cycling (95–60°C) for 40
cycles in a StepOne Plus RT-PCR detection system, fol-
lowing the instructions of the supplier (AB, Applied Bio-
system, USA). All samples were assayed in duplicate. The
results were normalized to the controls, and fold change of
the gene expression was calculated using threshold cycle
(Ct) values.
Total protein extraction from rat liver, isolated rat liver 
cells, and monocytic/macrophage cell line RAW 264.7
Total protein extracts were prepared from all controls,
TAA/CCl4-treated rat livers, and dissected CC tissues, as
well as from isolated hepatocytes, myoWbroblasts, KupVerHistochem Cell Biol (2012) 137:217–233 221
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cells, and RAW 264.7 cells. Tissues were washed in ice-
cold PBS to remove blood and homogenized at room tem-
perature in cell lysis buVer containing 7 mol/l urea, 2 mol/l
thiourea, 4% (w/v) CHAPS, 2% ampholytes, 1% (w/v) DL-
dithiothreitol and 10 mmol/l phenylmethylsulphonyl Xuo-
ride, as well as 1% (v/v) phosphatase inhibitor cocktail 1,
and 1% (v/v) phosphatase inhibitor cocktail 2 with a
homogenizer (Ultra-Turrax, Jahnke and Kunkel GmbH &
CO.KG, Staufen, Germany). The protein concentration was
calculated according to Bradford (1976) using the Bio-Rad
protein assay kit. The protein samples were stored at
¡80°C until further analysis.
1-DE/2-DE Western blot analysis of total protein lysates 
from rat liver tissue, isolated rat liver cells, 
and RAW 264.7cells
For 1-DE Western blot analysis, 50 g total protein was
loaded on a 4–12% NuPAGE Bis–Tris gel (Invitrogen,
Darmstadt, Germany) and separated for 2 h by electro-
phoresis at 80 V. For 2-DE Western blot analysis, 140 g
total protein lysate from rat liver tissues or from macro-
phage cell line RAW 264.7 and a trace of bromphenol
blue were loaded on immobilized pH gradient (IPG) strips
with a nonlinear pH range of 3–10. After rehydration, iso-
electric focusing was performed in a Protein IEF Cell
(Bio-Rad) at 20°C set to 32,000 Vh. The IPG strip was
equilibrated with equilibration buVer (6 mol/l urea, 30%
glycerine, 2% sodium dodecyl sulphate, 0.05 mol/l Tris/
5 N HCl to pH 8.8 and a trace of bromophenol blue) con-
taining 15 mmol/l DTT, followed with equilibration
buVer containing 40 g/l iodoacetamide. Afterwards, the
strip was loaded onto a vertical 12% polyacrylamide
SDS-PAGE for separation by molecular weight for 19 h at
4°C and 90 V. After Western blot, Ponceau staining was
performed as a control for successful protein transfer.
Nitrocellulose membranes were blocked in blocking
buVer containing 5% BSA and were incubated overnight
at 4°C with diVerent anti-COX-2 antibodies (33/Cox-2,
ab15191, sc-1746, sc-7951). The secondary antibodies
were conjugated with horseradish peroxidase. The mem-
branes were developed with an ECL chemiluminescence
kit (GE Healthcare, Munich, Germany). Antibodies and
dilutions used are listed in Table 1.
Silver-staining of proteins
2-DE gels were Wxed and washed and silver-staining was
performed according to the modiWed silver-staining method
of Blum et al. (1987). Gels were scanned (CanoScan
8400F, Canon) and Wnally dried for further storage (Gel
Dryer, Model 583; Bio-Rad).
Protein identiWcation
In-gel digestion was carried out according to a modiWed
protocol of Shevchenko et al. (1996). Spots of interest were
the positive spots from the ECL staining after 2-DE blots.
These were excised and after de-staining with potassium
ferricyanide and sodium thiosulphate; proteins/peptides
were digested with trypsin. Gel slices were washed and
equilibrated with ammonium bicarbonate followed by incu-
bation with acetonitrile (ACN). Peptides were extracted
using triXuoroacetic acid and ACN. Solutions with digested
protein/peptide were dried in a speed vacuum system
(UniEquip GmbH, Munich, Germany) and stored at ¡20°C
Fig. 1 Changes of COX-2 gene expression in rat liver tissue are
shown at various time points during (a) acute liver injury after TAA
(top) or CCl4 (bottom) administration and (b) chronic liver injury as
well as in dissected CC tissue after TAA administration. The graphics
represent the COX-2-speciWc mRNA amount normalized using UBC
as housekeeping gene. Error bars represent standard deviation (control
0h   n = 4, treatment n =4 ,  C C  n =4 ) .   h hours, w weeks, CC dissected
cholangiocarcinoma tissue, *P < 0.05 against control group according
to the Mann–Whitney U test222 Histochem Cell Biol (2012) 137:217–233
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until further analysis. Dried samples were diluted in 0.1%
formic acid and 1 l was loaded for chromatographic sepa-
ration on a CapLC-System (Waters, Milford, MA, USA).
Peptide sequence analysis was carried out on a Q-TOF
Ultima Global mass spectrometer (Micromass, Manchester,
UK) equipped with a nanoXow ESI Z-spray source in posi-
tive ion mode, as described previously (Schultze et al.
2010). Data were processed using Protein Lynx Global
Server (2.0, Micromass) and searched against MSDB and
SwissProt data bases through the Mascot search engine
with oxidation (M) and carbamidomethyl (C) modiWcation,
when appropriate.
Histochemical analysis and immunohistochemical 
investigations
Tissue sections were Wrst analyzed by hematoxylin and
eosin staining (HE). Liver tissue sections (5 m thick) of
three representative rats as well as three control rats were
analyzed at the following time points: 0, 24, 48, 96 h, 8,
Fig. 2 Immunolocalization of COX-2 protein by double immunoXuo-
rescence staining (CK-19, Hep Par-1, and ED1) in normal rat liver.
ImmunoXuorescence staining of a: COX-2 (red) and CK-19 (green);
b:C O X - 2  ( red) and Hep Par-1 (green); c: COX-2 (red) and ED1 (green).
Co-localization of COX-2 and ED1 is detectable. Polyclonal COX-2
antibody (ab15191) was used. The blue staining with DAPI represents
the nuclei (£100/£400 original magniWcation). pv portal vein, bd bile
duct. Bar 50 mHistochem Cell Biol (2012) 137:217–233 223
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16, and 18 weeks. Furthermore, specimens of four cir-
rhotic human livers after developing HCC or CC and four
specimens of cirrhotic liver without tumor were ana-
lyzed. After blocking of non-speciWc binding with 1%
BSA and 10% goat serum (DAKO, Hamburg, Germany)
containing PBS for 1 h at room temperature, two primary
antibodies were simultaneously incubated on the sections
overnight at 4°C. We used primary antibodies: rabbit
polyclonal anti-COX-2; mouse monoclonal anti-COX-2
(33/Cox-2), mouse monoclonal anti-CK-19; mouse
monoclonal anti-Hep Par-1; mouse monoclonal anti-
ED1, mouse monoclonal anti-CD68, and mouse mono-
clonal anti-ED2. Rabbit polyclonal antibodies were
detected with AlexaFluor-555-conjugated goat anti-rabbit
secondary antibody and mouse monoclonal antibodies
were visualized with AlexaFluor-488-conjugated goat
anti-mouse secondary antibody. Antibody dilutions used
are listed in Table 1.
In the double staining immunohistochemistry, ED1+/
COX-2+ positive cells were counted in Wve randomly
selected areas (0.51 mm2/area) in the centrilobular area of
the hepatic lobule at a magniWcation of 100£.
Fig. 3 Immunolocalization of COX-2, ED1 and ED2 in TAA-induced
acute rat liver injury (48 h). An immunoXuorescence staining of COX-
2- (red), ED1- (green, left side), and ED2¡ (green, right side) positive
cells is shown. Polyclonal COX-2 antibody (ab15191) was used. Stain-
ing with DAPI represents the nuclei (£100/£200 original magniWca-
tion). pv portal vein. Bar 50 m224 Histochem Cell Biol (2012) 137:217–233
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Negative control immunostainings were performed by
omission of the primary antibodies, use of non-immune
serum, and by isotype matching control immunoglobulin.
Sections were counter-stained with DAPI and observed
with an epiXuorescence microscope (Axiovert 200 M,
Zeiss, Jena, Germany).
Alkaline phosphatase anti-alkaline phosphatase (APAAP) 
technique
We used the mouse monoclonal anti-COX-2 antibody (33/
Cox-2) in this experiment. To make the antigen (COX-2)/
antibody reaction visible, the APAAP technique was
performed (Cordell et al. 1984). The APAAP complex is
stained with neufuchsin, which stains the COX-2-positive
cells red. The remaining tissue is made visible by counter-
staining with hematoxylin.
Statistical analysis
The data were analyzed with GraphPad Prism 4.0 software
(San Diego, USA) and SPSS (V14.0 for Windows; Chi-
cago, IL, USA). The results are shown as means § standard
deviation. SigniWcant diVerence was assessed at P <0 . 0 5
against the control group and calculated according to the
Mann–Whitney U test.
Fig. 4 Immunolocalization of COX-2, CK-19, Hep Par-1, and ED1 in
TAA-induced chronic rat liver injury (16 weeks). ImmunoXuorescence
staining of a: COX-2 (red) and CK-19 (green); b: COX-2 (red) and
Hep Par-1 (green); c: COX-2 (red) and ED1 (green). Co-expression of
COX-2 and ED1 is detectable only within regenerating nodules. Poly-
clonal COX-2 antibody (ab15191) was used. The blue staining with
DAPI represents the nuclei (£100/£400 original magniWcation).
RN regenerating nodules, CC cholangiocarcinoma. Bar 50 mHistochem Cell Biol (2012) 137:217–233 225
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Results
COX-2 gene expression in normal and damaged rat liver
COX-2 speciWc mRNA
COX-2 mRNA was detectable in normal liver tissue and
an upregulation up to 15-fold was detected during acute
(Fig. 1a) and chronic liver injury (Fig. 1b). SigniWcant
upregulation of COX-2 gene expression (P < 0.05) dur-
ing acute liver injury was observed 12 h (7.2 § 2.3-fold),
24 h (14.69 § 5.99-fold), 48 h (8.76 § 0.36-fold), and
72 h (4.48 § 1.2-fold) after TAA administration. Chronic
liver injury revealed signiWcant upregulation (P < 0.05)
after 12 weeks (4.31 § 0.65-fold), 16 weeks (3.56 §
0.65-fold), and 18 weeks of TAA administration (4.34 §
1.94-fold), as well as in dissected CC tissue (4.94 § 1.78-
fold).
Fig. 5 Immunolocalization of COX-2, CK-19, Hep Par-1, and CD68
in cirrhotic human liver. ImmunoXuorescence staining of a: COX-2 (red)
and CK-19 (green); b: COX-2 (red) and Hep Par-1 (green); c: COX-2
(red) and CD68 (green). Co-expression of COX-2 and CD68 is detectable
only within regenerating nodules. Polyclonal COX-2 antibody (ab15191)
was used. The blue staining with DAPI represents the nuclei (£100/£400
original magniWcation). pv portal vein, bd bile duct, RN regenerating
nodule. Bar 50 m226 Histochem Cell Biol (2012) 137:217–233
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Fig. 6 Immunolocalization of COX-2 after TAA-induced acute rat
liver injury (96 h). The following antibodies were used for immunohis-
tological staining: monoclonal COX-2 antibody (33/Cox-2), monoclo-
nal ED1 antibody (ED1) and monoclonal ED2 antibody (ED2). To
visualize the antigen/antibody reaction, the classic alkaline phospha-
tase antialkaline phosphatase (APAAP) technique was used. The
remaining tissue is made visible by counterstaining with hematoxylin.
a COX-2 in the undamaged liver of a control animal (100-fold magni-
Wcation). b Detail of a (400-fold magniWcation): a distinct COX-2 pos-
itivity is seen in cells (tissue macrophages) within the liver
parenchyma (black arrows). Scattered cells with a weak positivity can
be seen (white arrows) in the area of the portal Weld. c COX-2 after
TAA-induced acute rat liver injury (96 h). d Detail of c (400-fold mag-
niWcation): A weak COX-2 positivity is detectable in cells in the area
of injury (white arrows). e Serial section. In the area of damage a vari-
ety of cells (recruited inXammatory macrophages) with a signiWcant
ED1 positivity can be detected. f Detail of e (400-fold magniWcation).
g Serial section. ED2-positive cells are detectable in the area of injury.
The intensity in the area of injury is lower than in the area of the
undamaged parenchyma. h Detail of g (400-fold magniWcation). A
weak ED2 positivity is detectable in cells in the area of injury (black
arrows). Bar 50 mHistochem Cell Biol (2012) 137:217–233 227
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COX-2 localization in liver tissue
ImmunoXuorescence staining
Double immunoXuorescence staining was performed using
the polyclonal (ab15191) and/or monoclonal (33/Cox-2)
COX-2 antibody combined with antisera speciWc for CK-
19, Hep Par-1, ED1 or ED2.
In healthy adult rat liver, the bile duct epithelial cells
were strongly positive for CK-19, a typical bile duct cell
antigen. CK-19+ cells were COX-2¡ as were Hep Par1+
hepatocytes (Fig. 2a, b). Only ED1+/ED2+ cells (tissue
macrophages) in normal liver parenchyma were COX-2+
(Fig. 2c).
After administration of the toxins (TAA or CCl4), an
increasing number of ED1+/ED2¡ mononuclear cells
became detectable in the areas of damage. These cells
showed only a weak positivity for COX-2. In contrast, the
ED1+/ED2+ cells of the non-damaged tissue were clearly
COX-2+. There was no diVerence in the distribution
between ED1+ and COX-2+ cells (Fig. 3).
The cell counting performed in both models (TAA and
CCl4) of liver damage showed a signiWcant increase of the
total number of ED1+/COX-2+ cells after 24 h (1.4-fold) as
well as after 48 h (1.86-fold).
ED1+/COX-2+ cells located in the non-damaged area
were ED2+ as well. Their number was not signiWcantly
altered after 24 h (1.08-fold) and 48 h (0.73-fold) in com-
parison with the control.
ED1+/COX-2+ cells located in the damaged area were
predominantly ED2¡ and only a few cells with a weak
ED2+ were detectable. These cells showed a signiWcant
increase after 24 h (4.29-fold) and after 48 h (12-fold).
In chronically injured livers a strong increase of CK-19+
cells is observable but these CK-19+ cells remained COX-2¡
as did those localized within the CC region (Fig. 4a).
However, COX-2+ and ED1+/ED2+ cells were observed
within the “regenerating” nodules. While ED1+/ED2+ cells
within the regenerating nodules strongly correlated with
COX-2+ cells (ED1 and COX-2 co-localization), ED1+/
ED2¡ cells within the CC region were COX-2¡ (Fig. 4c).
In human cirrhotic livers, co-expression of CD68 (tissue
macrophages) and COX-2 was conWrmed in the “regener-
ating” nodules, whereas no co-expression of Hep Par-1
and COX-2, nor of CK-19 and COX-2 were observed
(Fig. 5). There was no diVerence between cirrhotic livers
after developing HCC or CC and cirrhotic livers without
tumor.
Immunohistochemistry by APAAP method
After speciWcity analysis performed by 2-DE Western blot
analysis and characterisation of the identiWed proteins we
realized the potentially non-speciWc binding of other proteins.
Fig. 7 Immunolocalization of COX-2 in TAA-induced cholangiocar-
cinoma. For immunostaining the monoclonal COX-2 antibody (33/
Cox-2) was used. To visualize the antigen/antibody reaction, the clas-
sic alkaline phosphatase antialkaline phosphatase (APAAP) technique
was used. The remaining tissue is made visible by counterstaining with
hematoxylin (£100/£400 original magniWcation). The black arrows
indicate COX-2-positive cells in the liver parenchyma. The white
arrows point to COX-2-positive cells within the tumor microenviron-
ment (lower images, 400-fold magniWcation). Tumor cells are COX-2
negative. Bar 50 m228 Histochem Cell Biol (2012) 137:217–233
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For immunohistochemistry with the APAAP method, we
used the COX-2 monoclonal antibody (33/Cox-2). The
results of APAAP staining of acute damaged livers con-
Wrmed the results of immunoXuorescence staining. Nonspe-
ciWc staining, particularly in the area of injury (“inXamed
hepatocytes”), did not appear (Fig. 6).
In the chronically damaged liver (tumor region), some
weakly COX-2+ cells were detectable within the tumor
microenvironment (Fig. 7).
COX-2 gene expression in a macrophage cell line RAW 
264.7 and in isolated rat liver cells
SpeciWty of the antibodies was controlled by using proteins
from macrophage cell line RAW 264.7 and isolated rat
liver macrophages. RAW 264.7 cells do not constitutively
express COX-2. However, the protein can be quickly
induced by treatment of the cells with endotoxin (Fig. 8a).
COX-2 protein was tested in isolated rat liver cells using
Western blotting (Fig. 8b). SpeciWc COX-2 protein band
(70 kDa) was clearly visible only in cultured KupVer cells
24 h after plating. As also isolated resident tissue macro-
phages constitutively express COX-2 gene treatment with
LPS aimed to show that COX-2 gene expression can be fur-
ther upregulated. RT-PCR analysis of total RNA revealed
an increase of COX-2 gene expression in isolated KupVer
cells after LPS-administration (Fig. 8c). COX-2 protein in
isolated fraction 3 (inXammatory) and 4 (resident) macro-
phages showed a higher total protein amount in fraction 4
than in fraction 3 48 h after CCl4-induced acute liver injury
(Fig. 8d).
2-DE Western blot analysis and speciWcity of antibodies
The speciWcity of the COX-2 antibodies was veriWed by
2-DE Western blot analysis and subsequently by mass spec-
trometric identiWcation of the corresponding spots in silver-
stained gels. We used total protein lysates from rat liver and
from RAW 264.7 cell line (as a positive control). We tested
three diVerent polyclonal COX-2 antibodies (ab15191,
sc-1746, sc-7951) and one monoclonal COX-2 antibody
(33/Cox-2).
Total protein of rat liver
The polyclonal antibody SC1746 revealed two clearly visi-
ble protein spots. One of these spots could be successfully
identiWed by mass spectrometry as Vimentin (VIME). The
polyclonal antibody SC7951 showed Wve protein spots.
Two of these spots could be successfully identiWed as Pro-
collagen-lysine, 2-oxoglutarate 5-dioxygenase 3 (PLOD3),
and heat shock 70 kDa protein 1A/1B (HSP71). The third
tested polyclonal antibody (ab15191) showed up several
clearly visible protein spots (Fig. 9, left side). The mass
spectrometric identiWcation of 12 protein spots revealed six
diVerent proteins (DnaJ homolog subfamily C member 3
(DNJC3), Alpha-enolase (ENOA), D-3-phosphoglycerate
dehydrogenase (SERA), Arginase-1 (ARGI1), Cystathionine
gamma-lyase (CGL), and Fructose-bisphosphate aldolase B
(ALDOB)). Arginase 1 was represented by six diVerent
protein spots. The monoclonal antibody (33/Cox-2) showed
no speciWc signal (data not shown). Neither the polyclonal
nor the monoclonal antibody detected COX-2 from the
2-DE-gel containing total protein lysates from rat liver.
Overall, a good correlation was found between the
observed and the calculated isoelectric point and molecular
weight of the identiWed proteins (Table 2; Suppl. Table 1).
Fig. 8 a COX-2 antibody binding was tested using protein from
macrophage cell line RAW 264.7 as a positive control. Total protein
extracts from unstimulated cells (RAW¡) and LPS/PMA-stimulated
cells (RAW+) were analyzed. b COX-2 protein expression in hepatocytes
(HCs), (myo)Wbroblasts (MFs), and KupVer cells (KCs) isolated from
rat liver. COX-2 protein (70 kDa) is clearly visible in isolated KCs.
-actin (43 kDa) was used as an internal standard. c COX-2 mRNA
expression increases in isolated KupVer cells after LPS-administration.
d Shown is the COX-2 protein amount in isolated macrophages after
CCl4-induced acute liver injury of fractions 3 (inXammatory macro-
phages) and 4 (resident macrophages)Histochem Cell Biol (2012) 137:217–233 229
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Total protein from the RAW 264.7 cell line
As a positive control, the total protein lysate of the macro-
phage cell line RAW 264.7 was used. The review of the
polyclonal (ab15191) and monoclonal (33/Cox-2) antibody
revealed a speciWc signal in the range of 70 kDa for both
antibodies. While the monoclonal antibody, however,
showed two spots in the region of 70 kDa, the polyclonal
antibody showed several additional spots in the range of
30–80 kDa, as was observable when total protein lysates
from rat liver tissue were used. The two spots of the mono-
clonal antibody were examined by mass spectrometry. One
protein spot could be successfully identiWed as Chain A,
Cyclooxygenase-2 (Prostaglandin Synthase-2) complexed
with a non-selective Inhibitor, Flurbiprofen (PGH2) (Fig. 9,
right side; Table 3; Suppl. Table 1). For the second spot no
corresponding protein spot in the silver-stained gel was
found.
Discussion
In this study we show that COX-2 is constitutively
expressed in macrophages of normal liver tissue and that
COX-2 gene expression increases in acutely, as well as in
chronically damaged liver in two rat models. Two diVer-
ent models of liver injury were studied in an attempt to
show that COX-2 gene is expressed in mononuclear
phagocytes of healthy and damaged liver independently
of the toxin used as well as in human liver tissue. The
increase is due to the increased expression in the resident
liver tissue macrophages and to recruited inXammatory
mononuclear phagocytes. Contrary to what we expected,
COX-2 immuno-detection in tumoral tissue is not found
in tumoral cells but only in those macrophages of the
tumor microenvironment and of the non tumoral tissue.
The constitutive COX-2 expression in tissue macrophages
was conWrmed in isolated rat KupVer cells. The results
obtained by the in vitro treatment of KupVer cells with
LPS indicates that the COX-2 expression can be further
stimulated in resident macrophages as suggested by the
data obtained in vivo.
COX-2 mRNA expression showed a signiWcant increase
at diVerent time points after TAA administration with a
maximum value after 24 h and during chronic liver injury
starting from 8 weeks of TAA administration. According to
immunohistology, this increase was not due to either the
“inXamed” hepatocytes (cells located around the inXamed
areas) (Chariyalertsak et al. 2001; Giannitrapani et al.
2009) or to the CC cells (Endo et al. 2002).
Administration of TAA or CCl4, two well-known
hepatotoxicants, altered not only epithelial cells, but also
provoked centrilobular inXammation/necrosis. The inX-
amed areas were populated mainly by inWltrating mono-
cytes/macrophages, identiWed by ED1 antigen expression
(Neubauer et al. 2008; Laskin et al. 2011; Zborek et al.
2006). In order to demonstrate that recruited inXammatory
mononuclear phagocytes may also be responsible for the
increase of COX-2 gene expression, double immunoXuo-
rescence staining studies were performed using anti-ED1,
anti-ED2 (Ramadori and Saile 2004), and anti-COX-2-anti-
bodies. Interestingly, COX-2 positivity was found not only
in the ED1+/ED2+ (resident) macrophages but also in the
ED1+/ED2¡ mononuclear phagocytes of the damaged areas
and of the tumor microenvironment. The presence of the
COX-2 protein was conWrmed in isolated inXammatory
phagocytes. In the past, COX-2 positivity in mononuclear
cells located within the tumor microenvironment was not
Fig. 9 Shown are the results from 2-DE Western blot analysis. After
ECL staining numerous spots are visible when the polyclonal antibody
(ab15191) and total protein from rat liver were used (left side). A spot
in the Weld of 70 kDa is not visible. The results of mass spectrometry
are indicated in the Wgure and marked with arrows. Using total protein
of the macrophage cell line RAW 264.7, two spots were visible (right
side). While one spot (in the range of 50 kDa) could not be located in
the silver-stained gel (small box), the evaluation of the second spot (in
the range just below 75 kDa) resulted in COX-2 (prostaglandin syn-
thase 2, PGH2). NI not identiWed230 Histochem Cell Biol (2012) 137:217–233
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underlined, but it is possible that these cells were responsi-
ble for the presence of the COX-2 mRNA level measured in
total RNA extracted from tissue samples (Bamba et al.
1999; Sheehan et al. 2005).
To be sure of the speciWcity of the diVerent available
antibodies, 2-DE and mass spectrometric analysis of COX-
2-positive protein spots were performed. The lack of any
speciWc signal in total protein lysates from rat liver for all
tested COX-2 antibodies in the range of 70 kDa could be
due to the small total amount of this protein and may be
partly due to limitations in the method used. To ensure that
2-DE is suitable for the detection of this protein, we used
(as a positive control) total protein lysates of the macro-
phage cell line RAW 264.7. And indeed, a speciWc binding
Table 2 Isoelectric point (pI), molecular weight (MW), and function of identiWed proteins in liver proteome using the indicated COX-2 antibodies
pI isoelectric point, obs. observed, calc. calculated
Protein name Spot label pI obs./calc. MW (kDa) 
obs./calc.
Function
COX-2 Abcam (ab15191), rabbit polyclonal
DnaJ homolog subfamily C member 3 DNJC3_RAT 5.8/5.62 51/57.5 Involved in the unfolded protein 
response (UPR) during ER stress
Alpha-enolase ENOA_RAT 6.6/6.16 47/47.1 Carbohydrate metabolism; glycolysis
D-3-phosphoglycerate dehydrogenase SERA_RAT 7.1/6.30 52/56.5 Amino-acid biosynthesis
Arginase-1 ARGI1_RAT 6.9/6.76 36/35.0 Nitrogen metabolism; urea cycle. 
Tissue speciWcity: detected 





Cystathionine gamma-lyase CGL_RAT 8.4/8.20 38/43.6 Catalyzes the last step in the 
transsulfuration pathway 
from methionine to cysteine. 
Converts two cysteine molecules 
to lanthionine and hydrogen sulWde
Fructose-bisphosphate aldolase B ALDOB_RAT 8.8/8.67 36/39.6 Carbohydrate metabolism; glycolysis
COX-2 Santa Cruz (SC1746), goat polyclonal
Vimentin VIME_RAT 5.3/5.06 70/53.7 Class-III intermediate Wlament
COX-2 Santa Cruz (SC7951), rabbit polyclonal
Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3 PLOD3_RAT 7.1/5.82 70/85.0 Forms hydroxylysine residues 
in collagens. Essential for the 
stability of the intermolecular 
collagen cross-links
Heat shock 70 kDa protein 1A/1B HSP71_RAT 6.6/5.61 74/70.1 Stabilize proteins against 
aggregation and mediate 
the folding of newly translated 
polypeptides. They bind 
extended peptide segments 
during translation and 
membrane translocation, 
or following stress-induced damage
COX-2 BD Transduction Laboratories (33/Cox-2), mouse monoclonal
./. ./. ./. ./. ./.
Table 3 Isoelectric point, molecular weight, and function of identiWed proteins in proteome of macrophage cell line RAW 264.7
pI isoelectric point, obs. observed, calc. calculated
Protein name Spot label pI obs./calc. MW (kDa) 
obs./calc.
Function
COX-2 BD Transduction Laboratories (33/Cox-2), mouse monoclonal
Chain A, Cyclooxygenase-2 (Prostaglandin Synthase-2) 
complexed with a non-selective inhibitor, Flurbiprofen
PGH2_MOUSE 7,3/6.86 73/67.2 Mediates the formation 
of prostaglandins from arachidonateHistochem Cell Biol (2012) 137:217–233 231
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of the monoclonal antibody (33/Cox-2) to COX-2 protein
could be detected by mass spectrometry. However, the
COX-2 protein spot in the total protein lysate of the macro-
phage cell line was a rather small protein spot. This could
be interpreted as a further indication of an only limited total
amount of this protein. This assumption is supported by the
absence of COX-2 detection in various other studies of pro-
teome of the liver conducted to date (Kawase et al. 2009; Li
et al. 2004; Sun et al. 2010).
The results of 2-DE were reXected also in immunohisto-
chemistry. The monoclonal antibody (33/Cox-2), whose
speciWc binding could be demonstrated, was strictly corre-
lated with ED1+ cells. In contrast, the polyclonal antibody
(ab15191) showed not only a clear correlation with ED1+
cells, but also a weak positivity in hepatocytes. However,
this antibody also binds to other proteins, including ARGI1.
ARGI1 is involved in the urea cycle and appears to play a
role in liver injury and NO synthesis (Reid et al. 2007). In a
recent study, ARGI1 was introduced as a possible new
immunohistochemical marker for hepatocytes and hepato-
cellular neoplasms (Yan et al. 2010). This may explain the
weak hepatocyte positivity detectable in the present study
using the polyclonal COX-2 antibody (ab15191).
Similar results are obtained with two other tested poly-
clonal COX-2 antibodies (SC1746, SC7951). Infact,
vimentin (VIME) was detected by the polyclonal COX-2
antibody SC1746 and recently described as a potential bio-
marker for HCC (Sun et al. 2010). Furthermore, COX-2
expression was described in hepatocytes during liver regen-
eration using COX-2 antibody SC7951 (Fernández-Martí-
nez et al. 2004). This antibody, however, in our hands also
binds to HSP71 which is upregulated in hepatocytes in liver
regeneration (Brockmann et al. 2005; Shi et al. 2007).
These potentially non-speciWc bindings, depending on the
antibodies used, may explain the conXicting results
reported in the literature regarding the hepatic COX-2
expression.
Conclusion
This work shows that COX-2 is constitutively expressed in
tissue macrophages of rat and human liver. Increase of
COX-2 gene expression in damaged liver tissue is due to
increased expression in resident macrophages and inXam-
matory cells which are also present in tumoral tissue. Chol-
angiocarcinoma cells of this model are COX-2 negative.
The contribution of mononuclear phagocytes should be
taken into account when total RNA extracted from tumoral
tissue is studied.
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